{"DataElement":{"publicId":"2685061","version":"5","preferredName":"Non-Hodgkin's Lymphoma Classification Type","preferredDefinition":"A description of non-Hodgkin lymphoma classification","longName":"2685048v1.0:2685057v3.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2685048","version":"1","preferredName":"Non-Hodgkin's Lymphoma Classification","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss.  The clinical course varies according to the morphologic type.  NHL is clinically classified as indolent, aggressive, or having a variable clinical course.  NHL can be of B-or T-/NK-cell lineage._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"NHL_CLASS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2676484","version":"1","preferredName":"Non-Hodgkin's Lymphoma","preferredDefinition":"Distinct from Hodgkin's lymphoma both morphologically and biologically, NHL lymphoma is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss.  The clinical course varies according to the morphologic type.  NHL is clinically classified as indolent, aggressive, or having a variable clinical course.  NHL can be of B-or T-/NK-cell lineage. --2003","longName":"C3211","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"393A575A-007A-282D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-03","modifiedBy":"ONEDATA","dateModified":"2007-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B73ACAE-0ABE-1FE4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-01","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2685057","version":"3","preferredName":"Non-Hodgkin Lymphoma Type","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss.  The clinical course varies according to the morphologic type.  NHL is clinically classified as indolent, aggressive, or having a variable clinical course.  NHL can be of B-or T-/NK-cell lineage._Something distinguishable as an identifiable class based on common qualities.","longName":"2685057v3.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Adult T-cell lymphoma / leukemia (HTLV1 associated)","valueDescription":"Acute Adult T-Cell Lymphoma/Leukemia","ValueMeaning":{"publicId":"2672900","version":"1","preferredName":"Acute Adult T-Cell Lymphoma/Leukemia","longName":"2672900","preferredDefinition":"The most common variant of adult T-cell lymphoma/leukemia.  It is characterized by systemic disease with a leukemic phase, generalized lymphadenopathy, and skin lesions.  Hypercalcemia is commonly seen. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Adult T-Cell Leukemia/Lymphoma","conceptCode":"C36265","definition":"The most common variant of adult T-cell leukemia/lymphoma.  It is characterized by systemic disease with a leukemic phase, generalized lymphadenopathy, and skin lesions.  Hypercalcemia is commonly seen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D674A7-099F-57D7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0D92-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Aggressive NK-cell leukemia","valueDescription":"Aggressive NK-Cell Leukemia","ValueMeaning":{"publicId":"2568138","version":"1","preferredName":"Aggressive NK-Cell Leukemia","longName":"2568138","preferredDefinition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive NK-Cell Leukemia","conceptCode":"C8647","definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D737-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0D9C-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Angioimmunoblastic T-cell lymphoma","valueDescription":"Angioimmunoblastic T-Cell Lymphoma","ValueMeaning":{"publicId":"2558224","version":"1","preferredName":"Angioimmunoblastic T-Cell Lymphoma","longName":"2558224","preferredDefinition":"A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites.  The clinical course is typically aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","conceptCode":"C7528","definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B07D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DA6-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Enteropathy-type T-cell lymphoma","valueDescription":"Enteropathy-Associated T-Cell Lymphoma","ValueMeaning":{"publicId":"3322761","version":"1","preferredName":"Enteropathy-Associated T-Cell Lymphoma","longName":"3322761","preferredDefinition":"An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enteropathy-Associated T-Cell Lymphoma","conceptCode":"C4737","definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A7B3-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DB0-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Extranodal marginal zone B-cell lymphoma of mucosal associated lymphoid tissue type (MALT)","valueDescription":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","ValueMeaning":{"publicId":"2593078","version":"1","preferredName":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","longName":"2593078","preferredDefinition":"MALT lymphoma.  A type of cancer that arises in cells in mucosal tissue that are involved in antibody production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C3898","definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A14-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DBA-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma)","valueDescription":"Grade 2 Follicular Lymphoma","ValueMeaning":{"publicId":"2593082","version":"1","preferredName":"Grade 2 Follicular Lymphoma","longName":"2593082v1.00","preferredDefinition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2 Follicular Lymphoma","conceptCode":"C8968","definition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A62-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DC4-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Follicular (grade unknown)","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"2558800","version":"1","preferredName":"Follicular Lymphoma","longName":"2558800","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B2BD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DCE-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"T-cell large granular lymphocytic leukemia","valueDescription":"T-Cell Large Granular Lymphocyte Leukemia","ValueMeaning":{"publicId":"2590775","version":"1","preferredName":"T-Cell Large Granular Lymphocyte Leukemia","longName":"2590775","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F6CF08-5979-36DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DD8-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Waldenstrom macroglobulinemia / Lymphoplasmacytic lymphoma","valueDescription":"Lymphoplasmacytic Lymphoma","ValueMeaning":{"publicId":"2629954","version":"1","preferredName":"Lymphoplasmacytic Lymphoma","longName":"2629954","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E665ACD-9834-52CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-18","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-04-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Added NCIt concept.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DE2-1FDC-E050-BB89AD4374E9","beginDate":"2010-04-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Mantle cell lymphoma","valueDescription":"Mantle Cell Lymphoma","ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DEC-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Mycosis fungoides","valueDescription":"Mycosis Fungoides","ValueMeaning":{"publicId":"2559297","version":"1","preferredName":"Mycosis Fungoides","longName":"2559297","preferredDefinition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4AE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0DF6-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Other B-cell lymphoma","valueDescription":"Other B-Cell Neoplasm","ValueMeaning":{"publicId":"3928504","version":"1","preferredName":"Other B-Cell Neoplasm","longName":"3928504","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas usually occur in adults and may be either indolent (slow-growing) or aggressive (fast-growing). There are many different types of B-cell lymphomas, and prognosis and treatment depend on the type and stage of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"B-Cell Neoplasm","conceptCode":"C27907","definition":"A lymphoproliferative disorder composed of neoplastic B-cells. It includes B-cell non-Hodgkin lymphomas, B-cell leukemias, plasma cell neoplasms, and B-cell proliferations of uncertain malignant potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-337B-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E00-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Peripheral T-cell lymphoma (PTCL), NOS","valueDescription":"Unspecified Peripheral T-Cell Lymphoma","ValueMeaning":{"publicId":"2672896","version":"1","preferredName":"Unspecified Peripheral T-Cell Lymphoma","longName":"2672896","preferredDefinition":"Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas.  This category includes the lymphoepithelioid cell variant of mature T-cell lymphoma (Lennert's lymphoma) and the T-zone variant of mature T-cell lymphoma.--2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C4340","definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D674A7-08B9-57D7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E14-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Extranodal NK / T-cell lymphoma, nasal type","valueDescription":"Nasal Type Extranodal NK/T-Cell Lymphoma","ValueMeaning":{"publicId":"2593089","version":"1","preferredName":"Nasal Type Extranodal NK/T-Cell Lymphoma","longName":"2593089","preferredDefinition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma.  It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells.  The nasal cavity is the commonest site of involvement.  Patients often present with midfacial destructive lesions (lethal midline granuloma).  The disease may disseminate rapidly to various anatomic sites including gastrointestinal tract, skin, testis, and cervical lymph nodes.  It is also known as angiocentric T-cell lymphoma.  The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma.  However, the latter term may also apply to lymphomatoid granulomatosis which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Type Extranodal NK/T-Cell Lymphoma","conceptCode":"C4684","definition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286BA529-8F3E-7325-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E1E-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Primary diffuse large B-cell lymphoma of the CNS","valueDescription":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","ValueMeaning":{"publicId":"3928506","version":"1","preferredName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","longName":"3928506","preferredDefinition":"A diffuse large B-cell lymphoma arising from the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","conceptCode":"C71720","definition":"A diffuse large B-cell lymphoma arising from the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-33C9-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E28-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Sezary syndrome","valueDescription":"Sezary Syndrome","ValueMeaning":{"publicId":"2560040","version":"1","preferredName":"Sezary Syndrome","longName":"2560040","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B795-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E32-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Splenic marginal zone B-cell lymphoma","valueDescription":"splenic marginal zone B-cell lymphoma","ValueMeaning":{"publicId":"2579748","version":"1","preferredName":"splenic marginal zone B-cell lymphoma","longName":"2579748","preferredDefinition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  The patients present with splenomegaly and the clinical course is indolent.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Splenic Marginal Zone Lymphoma","conceptCode":"C4663","definition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0491-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E3C-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Subcutaneous panniculitis-like T-cell lymphoma","valueDescription":"Subcutaneous Panniculitis-Like T-Cell ","ValueMeaning":{"publicId":"2560116","version":"1","preferredName":"Subcutaneous Panniculitis-Like T-Cell ","longName":"2560116","preferredDefinition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","conceptCode":"C6918","definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E46-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Anaplastic large-cell lymphoma (ALCL), ALK negative","valueDescription":"Anaplastic Large Cell Lymphoma, ALK-Negative","ValueMeaning":{"publicId":"3928514","version":"1","preferredName":"Anaplastic Large Cell Lymphoma, ALK-Negative","longName":"3928514","preferredDefinition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma, ALK-Negative","conceptCode":"C37194","definition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3BA7-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E50-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Anaplastic large-cell lymphoma (ALCL), ALK positive","valueDescription":"Anaplastic Large Cell Lymphoma, ALK-Positive","ValueMeaning":{"publicId":"3928516","version":"1","preferredName":"Anaplastic Large Cell Lymphoma, ALK-Positive","longName":"3928516","preferredDefinition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein.  Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma, ALK-Positive","conceptCode":"C37193","definition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm. It is characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein. Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3BCD-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E5A-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Primary cutaneous CD30+ T-cell lymphoproliferative disorders  [Primary cutaneous anaplastic large-cell lymphoma (C-ALCL), lymphoid papulosis]","valueDescription":"Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","ValueMeaning":{"publicId":"3928518","version":"1","preferredName":"Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","longName":"3928518","preferredDefinition":"This entity represents a spectrum of lymphoproliferative disorders characterized by CD30 (Ki-1)-positive cutaneous T-cell infiltrates.  The two ends of the spectrum include lymphomatoid papulosis (benign end) and primary cutaneous anaplastic large cell lymphoma (malignant end).  Borderline lesions are also included in this spectrum.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","conceptCode":"C7195","definition":"A spectrum of lymphoproliferative disorders characterized by CD30 (Ki-1)-positive cutaneous T-cell infiltrates. The two ends of the spectrum include lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3BF3-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E64-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Hepatosplenic T-cell lymphoma","valueDescription":"Hepatosplenic T-Cell Lymphoma","ValueMeaning":{"publicId":"2838581","version":"1","preferredName":"Hepatosplenic T-Cell Lymphoma","longName":"2838581","preferredDefinition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatosplenic T-Cell Lymphoma","conceptCode":"C8459","definition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-58F8-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E6E-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"T-cell / histiocytic rich large B-cell lymphoma","valueDescription":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","ValueMeaning":{"publicId":"3928520","version":"1","preferredName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","longName":"3928520","preferredDefinition":"A large B-cell lymphoma characterized by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","conceptCode":"C9496","definition":"A large B-cell lymphoma characterized by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3C2D-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E78-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma","valueDescription":"High Grade B-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"3928524","version":"1","preferredName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","longName":"3928524","preferredDefinition":"An aggressive lymphoma with morphologic features of both diffuse large B-cell lymphoma and Burkitt lymphoma, but without rearrangement of MYC gene, BCL2 gene and/or BCL6 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C80291","definition":"High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3C79-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E8C-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Burkitt lymphoma","valueDescription":"Burkitt Lymphoma","ValueMeaning":{"publicId":"2568284","version":"1","preferredName":"Burkitt Lymphoma","longName":"2568284","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt's lymphoma, Burkitt's lymphoma with plasmacytoid differentiation, and atypical Burkitt's/Burkitt's-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":"04/13/2011 - tc - Updated with current NCIt name and definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0E96-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Primary effusion lymphoma","valueDescription":"Primary Effusion Lymphoma","ValueMeaning":{"publicId":"2559886","version":"1","preferredName":"Primary Effusion Lymphoma","longName":"2559886","preferredDefinition":"An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV]. It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. The prognosis is extremely unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Effusion Lymphoma","conceptCode":"C6915","definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0EA0-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Primary mediastinal (thymic) large B-cell lymphoma","valueDescription":"Mediastinal (Thymic) Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838609","version":"1","preferredName":"Mediastinal (Thymic) Large B-Cell Lymphoma","longName":"2838609","preferredDefinition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Mediastinal Large B-Cell Lymphoma","conceptCode":"C9280","definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AEF5-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0EAA-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Intravascular large B-cell lymphoma","valueDescription":"Intravascular Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2947252","version":"1","preferredName":"Intravascular Large B-Cell Lymphoma","longName":"2947252","preferredDefinition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravascular Large B-Cell Lymphoma","conceptCode":"C4342","definition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74B9639F-F1F8-0172-E040-BB89AD436135","latestVersionIndicator":"Yes","beginDate":"2009-09-29","endDate":null,"createdBy":"SCOTTLO","dateCreated":"2009-09-29","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0EB4-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Follicular, predominantly large cell (Grade IIIB follicle center lymphoma)","valueDescription":"Grade 3b Follicular Lymphoma","ValueMeaning":{"publicId":"3928528","version":"1","preferredName":"Grade 3b Follicular Lymphoma","longName":"3928528","preferredDefinition":"A grade 3 follicular lymphoma composed of solid sheets of centroblasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3b Follicular Lymphoma","conceptCode":"C7192","definition":"A grade 3 follicular lymphoma composed of solid sheets of centroblasts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3D0B-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0EBE-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Follicular, predominantly large cell (Grade IIIA follicle center lymphoma)","valueDescription":"Grade 3a Follicular Lymphoma","ValueMeaning":{"publicId":"3928530","version":"1","preferredName":"Grade 3a Follicular Lymphoma","longName":"3928530","preferredDefinition":"A grade 3 follicular lymphoma in which centrocytes are present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3a Follicular Lymphoma","conceptCode":"C7191","definition":"A grade 3 follicular lymphoma in which centrocytes are present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3D31-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0EC8-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Diffuse, large B-cell lymphoma - NOS","valueDescription":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"3928526","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","longName":"3928526","preferredDefinition":"A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous and lack definitive and accepted criteria for further subclassification.  These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C80280","definition":"A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous. These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3CB3-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0ED2-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma)","valueDescription":"Grade 1 Follicular Lymphoma","ValueMeaning":{"publicId":"2593080","version":"1","preferredName":"Grade 1 Follicular Lymphoma","longName":"2593080","preferredDefinition":"A low-grade malignant lymphoma of predominantly follicular pattern. Follicles are of relatively uniform size and shape and the cells are usually somewhat larger than normal lymphocytes. Nuclei are irregular with prominent indentations and cytoplasm can rarely be identified. Cells exhibiting these characteristics are often called small cleaved cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1 Follicular Lymphoma","conceptCode":"C3465","definition":"A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A3B-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0EDC-1FDC-E050-BB89AD4374E9","beginDate":"2007-10-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Nodal marginal zone B-cell lymphoma (+/- monocytoid B-cells)","valueDescription":"Nodal Marginal Zone B-Cell Lymphoma","ValueMeaning":{"publicId":"2838642","version":"1","preferredName":"Nodal Marginal Zone B-Cell Lymphoma","longName":"2838642","preferredDefinition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Marginal Zone Lymphoma","conceptCode":"C8863","definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5AB3-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0EE6-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma","valueDescription":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"3928522","version":"1","preferredName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma","longName":"3928522","preferredDefinition":"A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classical Hodgkin lymphoma and diffuse large B-cell lymphoma.  This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classical Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gray-Zone Lymphoma","conceptCode":"C37869","definition":"A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classic Hodgkin lymphoma and diffuse large B-cell lymphoma.  This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classic Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3C53-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0FC5-1FDC-E050-BB89AD4374E9","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"Other T-cell / NK-cell lymphoma","valueDescription":"Other T-Cell Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"3113374","version":"1","preferredName":"Other T-Cell Non-Hodgkin Lymphoma","longName":"3113374","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A non-Hodgkin lymphoma of T-cell lineage.  It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T-Cell Non-Hodgkin Lymphoma","conceptCode":"C3466","definition":"A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89A00FFB-4682-5A58-E040-BB89AD430BEA","latestVersionIndicator":"Yes","beginDate":"2010-06-22","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32175E92-0FCF-1FDC-E050-BB89AD4374E9","beginDate":"2007-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2685056","version":"1","preferredName":"Non-Hodgkin's Lymphoma Type","preferredDefinition":"Distinct from Hodgkin's lymphoma both morphologically and biologically, NHL lymphoma is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss.  The clinical course varies according to the morphologic type.  NHL is clinically classified as indolent, aggressive, or having a variable clinical course.  NHL can be of B-or T-/NK-cell lineage. --2003:Type; a subdivision of a particular kind of thing.","longName":"C3211:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B82B1C1-80BA-34BB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-02","modifiedBy":"ONEDATA","dateModified":"2007-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32175E92-0D7B-1FDC-E050-BB89AD4374E9","latestVersionIndicator":"Yes","beginDate":"2016-05-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":".","administrativeNotes":"2023.8.9 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964924","version":"1","longName":"2400r1: Pre-TED","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PreTed_prime_dis_hct_nhl_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"pre_ted_who_nhl_spec","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_nhl_class","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_NHL_nhl_class","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"BRIDG mapping path for CDE:2685061","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.value(ANY=>CD).code","url":null,"context":"NHLBI"},{"name":"Specify the type of non-hodgk","type":"Preferred Question Text","description":"Specify the type of non-hodgkin lymphoma:","url":null,"context":"NHLBI"},{"name":"Specify Non-Hodgkin lymphoma classification","type":"Alternate Question Text","description":"Specify Non-Hodgkin lymphoma classification","url":null,"context":"NHLBI"},{"name":"Specify Non-Hodgkin lymphoma classification","type":"Application Standard Question Text","description":"Specify Non-Hodgkin lymphoma classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32175E92-0EFB-1FDC-E050-BB89AD4374E9","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-05-05","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}